Barclays PLC Foghorn Therapeutics Inc. Transaction History
Barclays PLC
- $854 Billion
- Q3 2025
A detailed history of Barclays PLC transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Barclays PLC holds 58,486 shares of FHTX stock, worth $274,299. This represents 0.0% of its overall portfolio holdings.
Number of Shares
58,486
Previous 70,814
17.41%
Holding current value
$274,299
Previous $334,000
14.67%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding FHTX
# of Institutions
88Shares Held
37MCall Options Held
100Put Options Held
0-
Flagship Pioneering Inc. Cambridge, MA12.7MShares$59.4 Million22.92% of portfolio
-
Bvf Inc San Francisco, CA5.3MShares$24.9 Million1.4% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.26MShares$15.3 Million0.3% of portfolio
-
Raymond James Financial Inc St. Petersburg, FL2.46MShares$11.5 Million0.0% of portfolio
-
Raymond James & Associates St Petersburg, FL2.3MShares$10.8 Million0.01% of portfolio
About Foghorn Therapeutics Inc.
- Ticker FHTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,637,400
- Market Cap $195M
- Description
- Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...